Global private equity and venture capital news and research

OrbiMed Advisors leads $30m for Audentes Therapeutics

19 Jul 2013

OrbiMed Advisors has led a $30m Series A round for San Francisco-based biotech company Audentes Therapeutics, which develops treatments for rare muscle diseases.

Sorry, to get access to this you need to subscribe for free.

In order to view more content, sign-up to our free daily newsletter.

If you would like to read the premium stories, have complete access to our breaking news and Limited Partner magazine you need to become a Premium Subscriber.

Subscribe to AltAssets today

Login to AltAssets

Legals & Terms of UsePrivacy Policy

AltAssets is registered as a trademark of Investor Networks Limited (06695690).
Registered Office: WeWork 4001, 1 Fore Street, London, EC2Y 5EJ
Content is © AltAssets 2000-2016